Redefining Rare Kidney Disase Treatments

Science that Transforms live

More

DETERA Therapeutics received SME status from EMA

DETERA Therapeutics @ LSX Lisbon March 2026

DETERA Therapeutics, winner of the Ipsen Golden Ticket 2025

DETERA Therapeutics received SME status from EMA DETERA Therapeutics @ LSX Lisbon March 2026 DETERA Therapeutics, winner of the Ipsen Golden Ticket 2025

DETERA Therapeutics @ BioLabs Hotel-Dieu, Paris

Pioneering the Future for Rare Neprhology with a Scalable Biotech Platform

We are an emerging player on the rare kidney diseases market for adults and children

OUR MISSION : Developing a portfolio of First-In-Class transformative therapeutic solutions

Our lead drug candidate DTR8 is developed for the treatment of Crescentic Glomerulonephritis (CGN), a severe condition with a high rate of therapeutic failure and associated costs.

DTR8 is a First-In-Class Disease-Modifying Drug for CGN. This is a first local, specific and immediate kidney therapy, with a compagnon test, allowing to stop the degradation of the kidney, preserve its function and decrease the number of patients under dialysis.

Redefining hope in rare kidney diseases

Meet DETERA Therapeutics @

  • DETERA Therapeutics @ LSX March 2026

  • DETERA Therapeutics @ BFM TV Nov. 2025

  • DETERA Therapeutics @ BIOEUROPE Nov. 2025

  • DETERA Therapeutics selected @ Biolab Investors Days March 2025

  • DETERA Therapeutics @ Vivatech Paris June 2025

Sections of the Website

Our Partners